OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Haematology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Issue Information	105
e‐Posters	87
Don't forget cord blood in non‐remission acute myeloid leukaemia!	81
Issue Information	75
A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction	69
Immunophenotypic clustering in paediatric acute myeloid leukaemia	67
Issue Information	59
Correction to “Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients”	58
	52
Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study	51
Population pharmacokinetics of high‐dose methotrexate and 7‐hydroxy methotrexate in Chinese adults with primary central nervous system lymphoma	49
Granulocyte colony‐stimulating factor may improve engraftment in adults with sickle cell disease undergoing non‐myeloablative haematopoietic stem cell transplantation	45
Unveiling the responsible antigen in vaccine‐induced immune thrombotic thrombocytopenia	45
The role of genetics in refractory immune thrombocytopenia	43
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial	42
The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant	40
Would you like to take some more ruxolitinib after your fedratinib?	39
Efficacy of ciclosporin monotherapy in non‐severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study	38
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia	38
Promises and challenges of artificial intelligence in haematological diagnostics	36
Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline	35
The impact of COVID‐19 vaccination on patients with a history of heparin‐induced thrombocytopenia	35
CAR T in patients with large B‐cell lymphoma not fit for autologous transplant	35
Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT)	35
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho	35

Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial	35
How to dose and monitor argatroban for treatment of HIT	34
Prolonged platelet hyperactivity after COVID‐19 infection	33
Whole‐exome sequencing uncovered genetic diagnosis of severe inherited haemolytic anaemia: Correlation with clinical phenotypes	33
ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning	33
R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203	33
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation	33
Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma	32
Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level	32
Myelodysplastic syndrome associated‐haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre	32